

1 **Title:** Spatially resolved human kidney multi-omics single cell atlas highlights the key role of the
2 fibrotic microenvironment in kidney disease progression

3 **Name of Authors:**

4 **Authors:** Amin Abedini^{1,2,3}, Ziyuan Ma^{1,2,3}, Julia Frederick^{1,2,3}, Poonam Dhillon^{1,2,3}, Michael S.
5 Balzer^{1,2,3}, Rojesh Shrestha^{1,2,3}, Hongbo Liu^{1,2,3}, Steven Vitale^{1,2,3}, Kishor Devalaraja-
6 Narashimha⁴, Paola Grandi⁵, Tanmoy Bhattacharyya⁶, Erding Hu⁶, Steven S. Pullen⁷, Carine M
7 Boustany-Kari⁷, Paolo Guarnieri⁷, Anil Karihaloo⁸, Hanying Yan⁹, Kyle Coleman⁹, Matthew
8 Palmer¹⁰, Lea Sarov-Blat⁶, Lori Morton⁴, Christopher A. Hunter¹¹, Mingyao Li⁹, Katalin
9 Susztak^{1,2,3*}

10 **Affiliations:**

11 ¹Renal, Electrolyte, and Hypertension Division, Department of Medicine, University of Pennsylvania, Perelman School of
12 Medicine, Philadelphia, PA 19104, USA

13 ²Institute for Diabetes, Obesity, and Metabolism, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA
14 19104, USA

15 ³Department of Genetics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA 19104, USA

16 ⁴Cardiovascular, Renal and Fibrosis Research, Regeneron Pharmaceuticals Inc., Tarrytown, NY 10591, USA

17 ⁵ Research and Development, GSK, Cellzome GmbH, Genomic Sciences, GSK, Heidelberg, Germany

18 ⁶ Research and Development, GSK, Crescent Drive, Philadelphia, Pennsylvania, USA

19 ⁷Department of Cardiometabolic Diseases Research, Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA.

20 ⁸Novo Nordisk Research Center Seattle, Inc., Seattle, USA

21 ⁹Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA,
22 USA

23 ¹⁰Department of Pathology and Laboratory Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia,
24 Pennsylvania, USA

25 ¹¹Department of Pathobiology, University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA, USA

26 **Correspondence:**

27 **Katalin Susztak, MD, PhD**

28 Professor of Medicine

29 University of Pennsylvania, Perelman School of Medicine

30 3400 Civic Center Blvd,

31 Smilow Translational building 12-123,

32 Philadelphia, PA 19104

33 Phone: (215) 898-2009

34 ksusztak@pennmedicine.upenn.edu

35 **Abstract**

36 Kidneys have one of the most complex three-dimensional cellular organizations in the body, but
37 the spatial molecular principles of kidney health and disease are poorly understood. Here we
38 generate high-quality single cell (sc), single nuclear (sn), spatial (sp) RNA expression and sn open
39 chromatin datasets for 73 samples, capturing half a million cells from healthy, diabetic, and
40 hypertensive diseased human kidneys. Combining the sn/sc and sp RNA information, we identify
41 > 100 cell types and states and successfully map them back to their spatial locations.
42 Computational deconvolution of spRNA-seq identifies glomerular/vascular, tubular, immune, and
43 fibrotic spatial microenvironments (FMEs). Although injured proximal tubule cells appear to be
44 the nidus of fibrosis, we reveal the complex, heterogenous cellular and spatial organization of
45 human FMEs, including the highly intricate and organized immune environment. We demonstrate
46 the clinical utility of the FME spatial gene signature for the classification of a large number of
47 human kidneys for disease severity and prognosis. We provide a comprehensive spatially-resolved
48 molecular roadmap for the human kidney and the fibrotic process and demonstrate the clinical
49 utility of spatial transcriptomics.

50

51 **Introduction**

52 Human kidneys filter over 140 liters of plasma, reabsorb all important nutrients, excrete water, and
53 electrolytes and eliminate toxins to maintain the internal milieu(1, 2). Kidney disease is defined
54 by a decline in glomerular filtration. Chronic kidney disease (CKD) is the 9th leading cause of
55 death(3, 4) in the United States, affecting 14% of the population. Diabetes and hypertension are
56 responsible for more than 75% of all CKD(5).

57 More than 30 specialized cell types including epithelial, endothelial, interstitial and immune cells
58 have been identified in the kidney(6, 7). The development of novel single cell and single nuclear
59 RNA-sequencing (scRNA-seq, snRNA-seq, respectively) as well as single nuclei Assay for
60 Transposase-Accessible Chromatin sequencing (snATAC-seq) have provided an unprecedented
61 insight into the molecular and cellular composition of healthy mouse and human kidneys as well
62 as changes during development and disease(8-12). These methods use dissociated cells or nuclei
63 isolated from kidney tissue samples. Despite the significant cellular diversity of the kidney, cell
64 types could be identified even after cell dissociation as specialized cellular function matches with
65 gene expression signatures, allowing investigators to estimate the location of cells (13).

66 The kidney is an architectural masterpiece. A critical limitation of dissociated single cell datasets
67 has been the lack of information on the spatial cellular context(14). Without spatial information, it
68 has been difficult to map known cell types that are only described by their anatomical location, for
69 example, cells that mostly provide structural support. The spatial context is also critical for
70 mapping cell types and cell states identified by novel single cell tools. We observe important
71 regional differences in disease severity, the dissociated single cell data is unable to interrogate
72 local gene expression changes and cell-cell communication, which plays a critical role in
73 maintaining cellular health and dysregulated in disease. Spatial omics analysis is a rapidly evolving

74 field. Currently available spatial datasets either lack single cell resolution information, are unable
75 to provide genome-scale gene expression data, or only evaluate a small spatial area (13, 15, 16).
76 There is a clear need for large-scale spatial omics datasets to better understand kidney health and
77 disease.

78 Chronic kidney disease (CKD), regardless of disease etiology, is associated with a complex change
79 in the kidney's cellular architecture(17). Some of the histological changes are specific for disease
80 type, such as thickening of glomerular basement membrane in diabetic kidney disease (DKD)(18).
81 Architectural changes, collectively called fibrosis, are present in all kidneys with advanced CKD.
82 The narrow definition of fibrosis focuses on accumulation extracellular matrix (19, 20). Most prior
83 studies, therefore, concentrated on understanding matrix accumulation in diseased organs. Matrix
84 accumulation can cause organ stiffness, which is likely responsible for organ failure in pulmonary
85 and heart fibrosis(21-23). As the role of tissue elasticity in kidney function regulation is not
86 immediately obvious(24), the mechanism by which matrix accumulation (or fibrosis) affects
87 kidney function has been controversial(25, 26). Kidney function only modestly correlate with
88 fibrosis ($r = 0.4$)(18, 27).

89 Here, we generated spRNA-seq data for healthy and diseased human kidneys in conjunction with
90 sn/scRNA-seq, snATAC-seq. By combining spatial gene expression with high quality single cell
91 expression and open chromatin information, we resolve the identity of cells previously only known
92 by their spatial localization and perform a detailed two-dimensional characterization of tissue
93 fibrosis. We demonstrate the cellular heterogeneity of the fibrotic stroma, which includes not only
94 immune and matrix-producing fibroblasts but also endothelial cells and immune cells that follow
95 the organization of a lymphoid organ that are anatomically close to injured proximal tubule cells.
96 We define tissue microenvironments, including the fibrotic microenvironment (FME) and show

97 that the FME gene signature can classify kidney samples and predict future kidney function
98 decline.

99

100 **Results**

101 **Spatially resolved multi-omics single cell survey of the healthy and diseased human kidneys**
102 **defines expression, gene regulation and spatial location of >100 cell types and states.**

103

104 We generated a comprehensive human kidney single cell and spatial resolution atlas by analyzing
105 73 human kidney tissue samples from 49 subjects (59.2% male and age of 63.75 ± 12.44 years).
106 Samples were divided into two groups: (i) healthy control (N=35) determined by estimated
107 glomerular filtration rate (eGFR) > 60 ml/min/1.73 m^2 and fibrosis < 5 % (ii) chronic kidney
108 disease (CKD) (N=38) determined by (eGFR) < 60 ml/min/1.73 m^2 or kidney fibrosis > 10 %
109 including 18 with diabetic kidney disease (DKD) and 20 with hypertensive kidney disease (HKD).

110 **Supplementary Table 1** shows the detailed demographic, clinical, and histological characteristics
111 of the included samples.

112 We performed droplet-based single cell analysis using 10X Chromium Next GEM (sc/snRNA-seq
113 (N=46) and snATAC-seq (N=20)) and used the Visium formalin-fixed paraffin embedded (FFPE)
114 tissue (N=7) platform for spRNA-seq. After standard processing and meticulous quality control
115 (QC), removing low-quality cells, we included 453,782 cells/nuclei into our final atlas.

116 **Supplementary Fig. 1** and **Supplementary Table 2** contains QC metrics of the included
117 samples. Overall, we could identify six cell super families, including endothelial cells, stromal
118 cells, tubule epithelial cells, immune cell types, glomerular cells, and neural cells. Clustering
119 identified 37 main and 111 distinct cell sub-types or states in healthy and diseased human kidneys

120 (Fig. 1, and Supplementary Fig. 2,3). Key cluster-specific gene markers are shown in Fig. 1,
121 Supplementary Fig. 3 and Supplementary tables 3 to 6. Our sc and sn human kidney atlas
122 captured all kidney cell types in healthy and disease status in all anatomical regions. The main
123 identified cell types were: podocytes, different types of proximal tubules segments 1-3 (PT_S1,
124 S2, S3, and injured), descending loop of Henle (DLOH), cortical and medullary thick ascending
125 loop of Henle (C_TAL and M_TAL), distal convoluted tubule (DCT), connecting tubule (CNT),
126 principal cells of collecting duct (PC), intercalated cells type alpha and beta (IC_A and IC_B),
127 stromal, and different types of immune cells.

128 The combination of single cell and single nuclear methods, the large number of analyzed cells, the
129 high-quality dataset, and inclusion of samples with different degrees of kidney disease severity in
130 our kidney atlas enabled the capture of rare and novel cell types. We could identify different
131 stromal cell types we called fibroblast_1 (*COL1A1+*, *COL1A2+*), fibroblast_2 (*VIM+*, *IGFBP7+*,
132 *B2M+*), and cells specifically present in sclerosed glomeruli (*CDH12+*, *CDH13+*) we called
133 GS_stromal cells (Fig. 1C, D, and Supplementary Fig 2,3). We could capture 19 different types
134 of endothelial cells and erythropoietin producing cells (Endo_peritubular_RAMP3+)
135 (Supplementary Fig. 3). We captured proximal tubule (PT) cells expressing high levels of
136 *SLC47A2*, specific for toxin excretion (Supplementary Fig. 2, 3 and Supplementary Table 6)
137 and tubule epithelial subtypes mostly seen in diseased kidneys that were positive for *CTSD*,
138 *CALB1*, *SPPI*, *CXCL14*.

139 Our atlas provides a comprehensive reference for human kidney immune cells. We could capture
140 all lymphoid (CD4T, CD8T, natural killer cells, T_regulatory, B_Naiive, B_memory,
141 plasma_cells) and myeloid cells (neutrophil, basophil/mast cells, CD14_monocyte,
142 CD16_monocyte, macrophage, classical and plasmacytoid dendritic cells). In summary, we were

143 not only able to generate the most comprehensive analysis of human kidney cells, including
144 multiple novel cell types, but these cell types were present in multiple analyzed samples and
145 captured by multiple analytical methods (sn/scRNA and snATAC analysis) (**Supplementary Fig.**
146 **4**).

147 In addition to the gene expression data, the snATAC-seq of 80,845 human kidney nuclei provided
148 us opportunities to identify transcription factors (TF) and enriched TF motifs in each cell type.
149 Cell gene-expression markers and a comprehensive list of cell types' differentially accessible
150 regions and transcription factors can be found in **Supplementary Fig 5, Supplementary Table 5,**
151 **7** and include *WT1* for podocyte and parietal epithelial cells (PEC), *HNF4A* for PT cell types,
152 *FOSL2* for injured_PT (iPT), and *TFAP2A* for C_TAL.

153 A key limitation to cell type identification has been the lack of high-resolution spatially resolved
154 cell transcriptomics information. To overcome this limitation, we used the new Visium FFPE
155 platform and generated seven spRNA-seq data sets, including two control (healthy) and five
156 diseased samples (3 DKD, 2 HKD) (**Supplementary Fig. 6**). We captured $2,043 \pm 374$ spots per
157 sample and detected $3,471 \pm 1,390$ genes per spot, providing an extremely rich dataset and
158 information (**Supplementary Fig. 6 and Supplementary Table 2**); enabling the identification of
159 all key kidney cell types (24 clusters) now at spatial level (**Supplementary Fig. 7**).

160 As a next step, we co-embedded the dissociated sc/snRNA-seq and snATAC-seq with the spRNA-
161 seq data, and generated an augmented high-resolution spatial dataset (94,696 datapoints) using
162 CellTrek(28). The high-resolution data enabled the projection of all identified cell types from the
163 dissociated datasets to its spatial location. Given differences in efficiencies of the cell capturing of
164 the scRNA and snRNA datasets, we generated three cellular resolution spatially resolved atlases
165 using our snRNA-seq (**Fig. 2**), scRNA-seq (**Supplementary Fig. 8**), and snATAC-seq

166 **(Supplementary Fig. 9)**. Via this method, we could successfully match the dissociated cell type
167 expression data to their anatomical, cellular locations including all types of tubules, different
168 interstitial cell types and endothelial cells. Furthermore, we could verify and highlight cell types,
169 such as iPT, previously observed in dissociated datasets without anatomical location. We could
170 identify markers for cell types previously only known by their anatomical location for instance,
171 PEC cells express *CFH*, *VCAN*, and *VCAMI* as well as mesangial cells express *ITGA8* and *POSTN*.
172 The different types of omics information (scRNA/snRNA/snATAC) provided a critical validation
173 for our datasets. Our computational kidney spatial map was consistent with the reading of our renal
174 pathologist as well as the Human Protein Atlas data **(Supplementary Fig. 10)**.
175 Overall, we constructed a high-quality spatially resolved human kidney multiome atlas, which
176 allowed the spatial mapping of high-resolution cellular and gene expression, gene regulatory
177 information in health and disease states. The entire dataset is now available for the community on
178 our easy-to-search website www.susztaklab.com.

179

180 **The presence and spatial proximity of injured proximal tubule cells to stromal cells indicates**
181 **their critical role in human kidney fibrosis**

182

183 To identify key cell types and mechanisms of fibrosis in DKD and HKD, we applied a variety of
184 unbiased computational tools. Differential gene expression (DEG) and accessible region (DAR)
185 analysis between healthy and CKD samples highlighted PT, stroma, and immune cell types with
186 the highest numbers of DEGs and DARs **(Supplementary Fig. 4)**. As fibrosis is patchy, it has
187 been difficult to understand driver pathways purely based on dissociated scRNAseq
188 information(29). To understand the proximity of cells, we performed an in silico cellular

189 deconvolution of the analyzed spots using our snRNA-seq dataset as a reference. We determined
190 the frequency when cells were captured together in the spatial data by running a correlation
191 analysis. We found that the coexistence correlation of cell types frequency follows the anatomical
192 regions in the kidney for example glomerular cells; glomerular endothelial cells, podocyte, PEC,
193 mesangial were mostly captured together. We observed a similar pattern for PT, iPT, LOH, and
194 distal tubes (**Fig. 3A, Supplementary Fig. 11A, 12, 13**). We found a strong correlation between
195 stromal, immune cells, and iPT cells, indicating their co-existence/proximity in the measured spots
196 (**Fig. 3A, Supplementary Fig. 11 A**). Healthy and diseased samples showed similar patterns.
197 However, the colocalization of stromal, immune, and iPT cell types was more robust in diseased
198 samples (**Supplementary Fig. 11B**).

199 Next, we generated an unbiased cell-cell distance matrix (measuring physical cell-cell distance) in
200 the Cell-Trek imputed spRNA-seq dataset (**Fig. 3B**). Similarly, to the spot deconvolution method,
201 we observed the proximity of glomerular cells and also the different types of fibroblast clusters
202 (**Fig. 3C, Supplementary Fig. 11C**). In this analysis, we found that PT cells, specifically injured
203 proximal tubules (iPT), were the most common scattered cells in the kidney, indicating that iPT
204 cells had the most diverse set of neighboring cells. We found that almost every kidney cell type;
205 especially stromal and immune cells, colocalized with iPT cells. In summary, differential
206 expression analysis indicated the high plasticity of PT cells and the close proximity of injured PT
207 cells to other cell types (**Supplementary Fig. 11-13**).

208 The spatial proximity and plasticity of PT cells made us focus on these cells. We found that the
209 fraction of iPT cells was markedly higher in diseased kidneys (**Fig. 3C**). However, we also
210 observed iPT cells in healthy kidneys. Using the single cell co-expression (SCoexp) module of
211 CellTrek(28) we identified two different iPT modules, corresponding to two iPT subtypes in

212 diseased samples (**Fig. 3D**) and one iPT type in healthy samples (**Supplementary Fig. 14**).
213 Moving back to the rich snRNA-seq data, we found that one iPT cluster was enriched for the
214 expression of *VCAM1*, *ACSL1*, *ASS1*, and *ASPA*, genes playing roles in cellular metabolism. We
215 called them iPT_*VCAM1*⁺. This cluster was more frequent in healthy samples. The second iPT
216 cluster expressed *HAVCR1* (or *KIM1*), *NFKBIZ*, *IL18*, *SPPI*, *ITGA3*, and *ITGB1* and was enriched
217 for genes associated with cell adhesion and matrix (iPT-*HAVCR1*⁺) (**Fig. 3E, Supplementary**
218 **Fig. 15**). Most iPT-*HAVCR1*⁺ cells were in the fibrotic samples. Trajectory analysis indicated that
219 iPT_*HAVCR1*⁺ were located at the end of pseudotime, suggesting that they have accrued greater
220 damage (**Fig. 3F**). Gene expression changes along the trajectory are listed in **Supplementary**
221 **Table 8**. Our snATAC-seq recapitulated our results (**Supplementary Fig. 16**). We identified
222 *TFEC* and *BACH2* as specific TFs for iPT_*VCAM1*⁺ and iPT_*HAVCR1*⁺, respectively (**Fig. 3G**).
223 Our results are consistent with prior snRNAseq results identifying *VCAM1*⁺ cells and prior
224 mechanistic studies recognizing *HAVCR1*⁺ as an injured PT marker (10).
225 iPTs were often captured together with stromal cells and were the closest to stromal fibroblasts
226 (**Supplementary Fig. 17**). Our trajectory analysis indicated a continuous transition between iPT
227 and fibroblasts similar to the previously described epithelial-mesenchymal transition (EMT)(30,
228 31) including the expression of *ZEB1*, *ZEB2*, *SNAI2*, and *ACTA2* (**Supplementary Fig. 17, 18**).
229 Module analysis of the spRNA-seq dataset highlighted fibroblast_1 and fibroblast_2 subtypes with
230 different characteristics; fibroblast_1 was enriched for matrix protein expression and fibroblast_2
231 for inflammatory genes (**Supplementary Fig. 17, 19**).
232 In summary, differential expression analysis indicated highly plastic PT cells and the close
233 proximity of injured PT cells to the fibrotic stroma. Using spatial profiling, we could identify two

234 types of injured PT cells (VCAM1+ and HAVCR1+) in healthy and diseased samples and show
235 their close proximity to fibroblasts.

236

237 **Fibroblast heterogeneity in human kidney disease**

238 To further examine fibroblast heterogeneity and its relationship to the development of fibrosis, we
239 created an extracellular matrix (ECM) score by calculating the expression of collagen,
240 glycoprotein, and proteoglycan specific genes in different cell types(32, 33). **Fig. 4A** shows that
241 fibroblast_1, 2, MyoFib/VSMC, and mesangial cells had the highest ECM score. Consistently,
242 fibroblast_1, and VSMC/myofibroblast fractions were higher in diseased samples (**Fig. 4B**). The
243 ECM score was consistent with the presence of fibroblasts in the spRNA-seq data, which was
244 compatible with the presence of these cells (**Fig. 4C**).

245 Sub-clustering analysis of stromal cells identified 10 different cell types, including 6 different
246 fibroblasts; SERPINE1+, FAP+, COL1A1+, CR2+, B2M+, and CXCL14+ fibroblasts. The sub-
247 clustering also indicated *REN*-expressing juxtaglomerular cells and *ITGA8* and *POSTN*-expressing
248 mesangial cells. We could discriminate VSMC expressing *MYH11*, *RSG6*, and myofibroblast
249 expressing *ACTA2* and *SYNPO2* (**Fig 4. D**). While several snRNA-seq studies proposed stromal
250 cell subtypes, our spRNA-seq dataset provides an unbiased verification and spatial localization for
251 these cells (**Fig 4. E**). Our spRNA-seq data was consistent with protein expression in the Human
252 Protein Atlas (**Supplementary Fig. 20**) and by snATAC-seq analysis (**Supplementary Fig. 21**).

253 Within the stromal cells, SEPRINE1+, COL1A1+, FAP+ cells, and myofibroblast had the highest
254 ECM score. Consistently, this cell type was enriched in diseased kidneys compared to controls
255 (**Fig. 4F**). Cell trajectory analysis indicated that myofibroblasts are located at the end of pseudo
256 time originating from pericytes, as previously shown(32) (**Supplementary Fig. 22**,

257 **Supplementary Table 9**). Using the snATAC-seq data, we could identify *TCF12* for SERPINE1+
258 and *E2FI* transcription factor motifs in myofibroblast (**Fig. 4G, Supplementary Fig. 21**).

259

260 **The interaction of stromal, immune, endothelial and injured epithelial establishes the kidney** 261 **fibrotic microenvironment**

262 Our newly generated spRNA-seq dataset is uniquely suited to defining microenvironments (ME)
263 in the human kidney. We ran nonnegative matrix factorization (NMF) on the spRNA-seq datasets.
264 We found four major MEs in the human kidney, including glomerular/vascular MEs, tubule MEs,
265 fibrotic MEs (FMEs), and immune MEs. The gene ontology enrichment analysis of genes detected
266 in each microenvironment was consistent with their anatomical annotation (**Supplementary Fig.**
267 **23**). It is important to note that the method identified patchy areas in the kidneys that were labelled
268 as fibrotic microenvironments. The computationally defined FME strongly correlated with kidney
269 ECM scores (**Fig. 5A, Supplementary Fig. 24**) and our pathologist's assessment of fibrosis. Cell
270 type enrichment analysis indicated iPT, fibroblast_1, fibroblast_2, and different immune cell types
271 around the endothelial cells in FMEs (**Fig. 5B, Supplementary Fig. 24, 25**).

272 We also identified a specific immune ME. These immune MEs were located within the FME, but
273 again with patchy distribution. The immune ME consisted of follicular dendritic cells, plasma
274 cells, B-cell and T lymphocytes (**Supplementary Fig. 26**). The immune ME organizations
275 resembled early tertiary lymphoid structures(34). Immunostaining studies with cell type specific
276 antibodies validated the presence of these specific immune cells and immune cell aggregates
277 (**Supplementary Fig. 27**).

278 To further understand cell interactions in FMEs, we implemented CellChat(35) on sn/scRNA-seq
279 and spRNA-seq datasets. We found enrichment for *C3*, *IL7*, *SPPI*, *IL17A*, *CXCL12*, *CXCL13*,

280 *CCL19*, *CCL21*, *PDGFB*, *TGFBI* and their receptors in FME regions (**Fig. 5C, D, Supplementary**
281 **Fig. 28**). We observed that *iPT_HAVCR1+* expressed *IL7*, *C3*, and *SPPI* while their receptors
282 were present on CD4T, CD8T, macrophages, and stromal cells, respectively, indicating that *iPT*
283 cells might be responsible for the influx of these cells (**Supplementary Fig. 28, 29**). The stromal
284 cells in FME were enriched for chemotactic factors including *CXCL12*, *CXCL13*, *CCL19*, *CCL21*
285 and while their receptors were expressed in different immune cell, suggesting that stromal cells
286 might signal to immune cell. We observed expression of *PDGFB* and *TGFBI*, known mediators
287 of fibrosis, in FME associated immune aggregates (**Fig. 5 C, D**). CellChat analysis of sn/scRNA-
288 seq and spRNA-seq indicated FME stromal cells with the highest secretory score (**Supplementary**
289 **Fig. 28, 29**).

290 Overall, using unbiased NMF we identified spatial kidney regions, including well established
291 glomerular and tubular regions, but also fibrotic and immune regions. Most importantly, FMEs
292 were not only characterized by matrix-producing fibroblasts but we identified an intricate cell-cell
293 interaction, indicating a complex cellular architecture (**Fig. 5E**).

294

295 **Fibrotic microenvironment gene signature successfully predicts disease prognosis in a large**
296 **cohort of human kidney samples.**

297 Next, to understand whether our spatially resolved human kidney atlas information can be used
298 for disease classification and prognosis evaluation, we analyzed a large cohort of human kidney
299 samples. We first generated an FME gene signature (FME-GS) (**Supplementary Table 10**) and
300 analyzed our large external kidney cohorts' gene expression data from 298 human kidney samples
301 (**Fig. 6A**), including healthy samples and samples with varying severity of DKD and HKD.

302 Our FME-GS was able to successfully cluster 298 human kidney samples into 3 separate groups
303 (**Fig. 6B**). These 3 groups corresponded to samples with varying degrees of disease severity as
304 indicated by differences in clinical parameters such as eGFR and fibrosis (**Fig. 6B**) (despite the
305 fact that these parameters were not included in the clustering algorithm).

306 Next, we wanted to know whether FME-GS could be used as a disease prognostic marker. Here
307 we used a different set of large external human kidney gene expression datasets (N = 218), with a
308 mean follow-up time of 2.49 (SD: 1.96) years. Our FME-GS successfully clustered samples based
309 on disease severity (**Fig. 6C**). The top FME genes showing the greatest difference between clusters
310 were mostly stromal and immune cell specific genes, including *PDGFB*, *MYH9*, *NFKB1*, and
311 *STAT3* (**Fig. 6D**). Next, we analyzed the relationship between cell types and kidney disease
312 progression. We found that genes correlated with eGFR slope were enriched in PT, stromal and
313 immune cells (**Fig. 6E**). Finally, we performed a Kaplan-Meier analysis to predict the probability
314 of reaching to end stage kidney disease (eGFR < 15 ml/min/1.73 m²) or 40% eGFR decline/year.
315 These are hard outcomes identified by the FDA for drug effectiveness(36). Our data indicated that
316 cluster 1, with the highest FME-GS score, had the highest hazard ratio to reach the end-point (**HR**
317 **= 3.61, 95%CI: 1.25 – 10.4**). We found that FME-GS has the strongest predictive value when
318 compared to other microenvironments (**Supplementary Fig. 30**).

319 In summary our spatially derived FME-GS can identify subjects with progressive kidney function
320 decline in a large cohort.

321

322 **Discussion**

323 Here we present the spatial molecular principles of kidney health and disease via generating a
324 comprehensive and spatially resolved human kidney atlas by combining single cell omics data and

325 a large number of human kidney tissue samples with varying degrees of disease severity. Our work
326 fills a critical knowledge gap by characterizing cell types previously only defined by their spatial
327 location, showing the anatomical location of cells only observed in dissociated single cell
328 expression data and defining cell-type specific gene expression changes in diseased areas. We
329 define the cellular complexity of the fibrotic microenvironment as the intricate interaction of a
330 large number of cell types. We demonstrate the clinical prognostic value of spatial transcriptomics.

331
332 Previous single cell analyses, focusing on dissociated human and mouse kidney datasets, have
333 generated gene expression and regulatory matrices for a variety of kidney cell types(8-12, 37). As
334 kidney cell types have been functionally well characterized, most identified cell types have been
335 matched back to a more than half-century old functional cell type definition(6). A key limitation
336 of these analyses has been the identification and molecular characterization of anatomically
337 defined cell types, such as mesangial cells, PEC cells, and fibroblasts. Here we demonstrate that a
338 joint approach that includes large single cells, single nuclear expression, open chromatin, and
339 spRNA-seq combined with large and diverse samples and large cell numbers is critical to achieve
340 this goal. The orthogonal analytical tools provide unique opportunities for validation, as each
341 method suffers from specific technological biases. Here, we have not only been able to resolve and
342 validate previously anatomically-known cell types but also identify novel cell types such as
343 specific stromal cells for glomerulosclerosis (expressing *CDH13*)(38).

344
345 Fibrotic diseases are responsible for close to 40% of all deaths(39). Kidney fibrosis is the final
346 common pathway to end stage kidney failure(40). Fibrosis, however, is an anatomically defined
347 lesion and most emphasis has been placed on matrix accumulation and characterization of matrix

348 producing cells. Here, we demonstrate the cellular and architectural complexity of kidney fibrosis.
349 We propose the use of the fibrotic microenvironment to characterize these lesions, to not only
350 focus on matrix accumulation but on the elaborate cellular complexity of these lesions. We show
351 that they are anatomically localized close to injured PT, indicating that iPT is likely to be an
352 important nidus of fibrosis. We identify spatially defined iPT subtypes. These iPT subtypes are
353 consistent with previous mechanistic studies and animal model single cell data (10). Furthermore,
354 our data suggest that some iPT cells can directly convert into fibroblasts, consistent with the
355 previously proposed EMT hypothesis(30, 31).

356
357 Combining snRNA and spatial information, we not only define the stromal cell subtypes but also
358 the cellular and architectural heterogeneity of fibrosis. We could conclusively discriminate VSMC
359 and mesangial cells from myofibroblasts that are anatomically distinct but share gene expression
360 signatures in sc/snRNAseq data(41-43). We identify two key fibroblast modules; matrix secreting
361 and immune fibroblast and show 10 different stromal cell types. We identify the key cell types that
362 contribute to ECM production. Our data indicates that fibroblasts are the precursors of
363 myofibroblasts in the kidney, but tubule cells could also become fibroblasts(32). We could identify
364 novel markers and, ultimately, new fibroblast types and determine their spatial location. This
365 information could be important in the field of finding therapeutic candidates for renal fibrosis. We
366 noted a large cluster of FAP-positive fibroblasts in diseased human kidneys(44-46). FAP targeted
367 cellular and RNA therapies have been developed and shown to have efficacy animal models of
368 cardiac fibrosis(44-46). Our data suggests that these therapeutics may be helpful for treating
369 kidney fibrosis.

370

371 Most importantly, we demonstrated that human kidney fibrosis is an established
372 microenvironment, not just a simple collagen accumulation problem. The interaction of a large
373 number of cell types, including iPT, immune, stromal, and endothelial cells, establishes the FME.
374 While we did not perform side-by-side comparison, the cell heterogeneity and cell interaction
375 network of human kidney fibrosis appear far more complex than what has been published for
376 mouse models(47, 48). For example, in mice, we identified a large number of secreted cytokines
377 from iPT cells responsible for the influx of immune and stromal cells(48). In patient samples, there
378 is a strong interaction between stromal and immune cells and also signaling by immune and
379 stromal cells to iPT, which might play a role maintaining their injured PT state.

380
381 Immune cell clusters have long been observed in fibrotic kidney samples, even in patients with
382 non-immune-mediated kidney disease, such as diabetes and hypertension(40, 49). Here we resolve
383 these regions both spatially and at a cell type level. Our kidney scRNA-seq data was enriched for
384 immune cells and enabled us to spatially resolve immune cell types and determine the distributions
385 of immune cells in the kidney. We show that immune cell clusters (the immune microenvironment)
386 are localized mostly within some FMEs. While we did not perform a systematic comparison of
387 human and mouse kidney fibrosis, our data indicate lymphocyte prominence compared to myeloid
388 cells in human fibrosis, while mouse fibrosis models are strongly enriched for macrophages(48).
389 The fibrosis-associated immune aggregates show a resemblance to the tertiary lymphoid structures
390 (TLS). TLS are organized aggregates of immune cells that form postnatally in nonlymphoid
391 tissues, usually as a persistent antigen production(50) and generate autoreactive effector cells. TLS
392 have been earlier described in mouse kidney tissue samples(51-54). Future studies will be needed

393 to define TLSs in CKD and kidney fibrosis; however, they could have tremendous therapeutic
394 potential.

395

396 One of the most devastating complications of CKD is its progression to ESRD, which requires
397 life-sustaining dialysis or transplantation (55). At present, we cannot predict which patients will
398 progress to ESRD, representing an important clinical problem. Our data indicate that FME-GS
399 can identify subjects at risk of ESRD in a large external dataset of human kidney tissue samples.

400 These results establish FME-GS as a key biomarker and potentially as a causal mechanism of
401 progression.

402 In summary, we develop a spatially defined molecular human kidney cellular atlas, characterize
403 the fibrotic microenvironment, and indicate their role as a clinically meaningful prognostic disease
404 biomarker, demonstrating the utility of spRNA-seq for the investigation complex diseases.

405 .

406

407

408

409

410

411

412

413 **Methods:**

414 **Single nuclei RNA sequencing**

415 Nuclei were isolated using lysis buffer (Tris-HC, NaCl, MgCl₂, NP40 10%, and RNase inhibitor
416 (40 U/ul)). 10-30 mg of frozen kidney tissues were minced with razor blade into 1-2 mm pieces in
417 1 ml of lysis buffer. The chopped tissue was transferred into a gentleMACS C tube and tissue was
418 homogenized in 2 ml of lysis buffer using gentleMACS homogenizer with programs of
419 Multi_E_01 and Multi_E_02 for 45 seconds. The homogenized tissue was filtered through a 40
420 µm strainer (08-771-1, Fisher Scientific) and the strainer was washed with 4 ml wash buffer.
421 Nuclei were centrifuged at 500xg for 5 minutes at 4°C. The pellet was resuspended in wash buffer
422 (PBS 1X + BSA 10% (50 mg/ml), + RNase inhibitor (40 U/ul)), filtered through a 40 µm Flowmi
423 cell strainer (BAH136800040-50EA, Sigma Aldrich). Nuclear quality was checked, and nuclei
424 were counted. In accordance with the manufacturer's instructions, 30,000 cells were loaded into
425 the Chromium Controller (10X Genomics, PN-120223) on a Chromium Next GEM chip G Single
426 Cell Kit (10X Genomics, PN-1000120) generate single cell gel beads in the emulsion (10X
427 Genomics, PN-1000121). The Chromium Next GEM Single Cell 3' GEM Kit v3.1 (10X
428 Genomics, PN-1000121) and Single Index Kit T Set A (10X Genomics, PN-120262) were used in
429 accordance with manufacturer's instructions to create the cDNA and library. Libraries were
430 subjected to quality control using the Agilent Bioanalyzer High Sensitivity DNA kit (Agilent
431 Technologies, 5067-4626). The following demultiplexing was used to sequence libraries using the
432 Illumina Novaseq 6000 system with 2 × 150 paired-end kits: 28 bp Read1 for cell barcode and
433 UMI, 8 bp I7 index for sample index, and 91 bp Read2 for transcript.

434

435 **Single nuclei ATAC sequencing**

436 The procedure described above was used to isolate the nuclei. The resuspension was performed in
437 diluted Nuclei Buffer (10X GEM). Nuclei quality and concentration were measured with Countess
438 AutoCounter (Invitrogen, C10227). The diluted nuclei were loaded and incubated in chromium
439 single cell ATAC library & gel bead kit's transposition mix (10X Genomics, PN-1000110).
440 Chromium Chip E (10X Genomics, PN-1000082) in the Chromium Controller was utilized to
441 capture the GEMs. The Chromium Single Cell ATAC Library & Gel Bead Kit and Chromium i7
442 Multiplex Kit N Set A (10X Genomics, PN-1000084) were then used to create snATAC libraries
443 in accordance with the manufacturer's instructions. Library quality was examined using an Agilent
444 Bioanalyzer High Sensitivity DNA kit. Libraries were demultiplexed, as follows, after sequencing
445 on an Illumina Novaseq system using two 50-paired-end kits: 50 bp Read1 for DNA fragments, 8
446 bp i7 index for sample index, 16 bp i5 index for cell barcodes, and 50 bp Read2 for DNA
447 fragments.

448 **Single Cell RNA-seq**

449 Fresh human Kidneys (up to 0.5 gr) collected in RPMI were minced into approximately 2-4 mm
450 cubes using a razor blade and then transferred to a gentleMACS C tube contains Multi Tissue
451 dissociation kit 1 (Miltenyi, #130-110-201). The tissue was homogenized using Multi-B program
452 of gentleMACS dissociator with Multi_B program in the tube contains 100ul of Enzyme D, 50ul
453 of Enzyme R and 12.5ul of Enzyme A in 2.35 ml of RPMI and incubated for 30mins at 37 degrees.
454 Second homogenization were performed using Multi_B program on gentleMACS dissociator. The
455 solution was then passed through a 70um cell strainer. After centrifugation at 1,200 RPM for
456 7mins, cell pellet was incubated with 1ml of RBC lysis buffer on ice for 3mins. The reaction was

457 stopped by adding 10 ml PBS. Next the solution centrifuged at 1,000 RPM for 5 minutes. Finally,
458 after removing the supernatant, the pellet was resuspended in PBS. Cell number and viability were
459 analyzed using Countess AutoCounter (Invitrogen, C10227). This method generated single cell
460 suspension with greater than 80% viability. Next, 30,000 cells were loaded into the Chromium
461 Controller (10X Genomics, PN-120223) on a Chromium Next GEM chip G Single Cell Kit (10X
462 Genomics, PN-1000120) to generate single cell gel beads in the emulsion (GEM) according to the
463 manufacturer's protocol (10X Genomics, PN-1000121). The cDNA and library were made using
464 the Chromium Next GEM Single Cell 3' GEM Kit v3.1 (10X Genomics, PN-1000121) and Single
465 Index Kit T Set A (10X Genomics, PN-120262) according to the manufacturer's protocol. Quality
466 control for the libraries were performed using Agilent Bioanalyzer High Sensitivity DNA kit
467 (Agilent Technologies, 5067-4626). Libraries were sequenced on Illumina Novaseq 6000 system
468 with 2 × 150 paired-end kits using the following demultiplexing: 28 bp Read1 for cell barcode and
469 UMI, 8 bp I7 index for sample index and 91 bp Read2 for transcript.

470 **Visium FFPE for SpRNA-seq**

471 RNA quality of human kidney FFPE sample was checked by extracting RNA using RNeasy FFPE
472 kit (Qiagen-Cat #73504) according to the manufacturer's protocol. RNA quality was examined
473 using Agilent bioanalyzer and samples with DV200>50% were selected. Then a 5 µm tissue
474 samples was cut onto the Visium Spatial gene Expression Slide. After deparaffinization, H & E
475 staining was performed. We used Keyence 1266 BZ-X810 microscope for whole slide imaging.
476 After scanning, de-crosslinking, probe hybridization, probe release and extension, library
477 preparation was performed by single Index Kit TS Set A (10X Genomics, PN-3000511) according
478 to manufacturer's protocol. Quality control for the libraries were performed using Agilent

479 Bioanalyzer High Sensitivity DNA kit (Agilent Technologies, 5067-4626). Libraries were
480 sequenced on Illumina Novaseq 6000 system with 2×150 paired-end kits using the following
481 demultiplexing: 28 bp Read1 for cell barcode and UMI, 10 bp I7 index, 10bp i5 index and 50 bp
482 Read2 for transcript.

483 **Microdissection and Bulk RNA sequencing**

484 Under a dissecting microscope, human kidney tissues were microdissected in RNA-later solution
485 using a microdissection forceps. After removing glomeruli, the remaining tissue was treated as a
486 tubule. Total RNA was extracted using the Qiagen RNeasy kit (catalog #74106). Agilent
487 Bioanalyzer RNA 6000 Pico kit (Agilent Technologies, 5067-1513) was used to assess the quality
488 of the RNA. All samples with an RNA integrity number (RIN) of at least 6 were utilized. Following
489 the manufacturer's instructions, strand-specific RNA-seq libraries were created using the
490 NEBNext® Ultra™ RNA Library Prep Kit for Illumina (catalog #E7530L). RNA-seq libraries
491 were then sequenced to a depth of 20 million 2×150 pair end reads.

492 **Human Sample Acquisition**

493
494 Left-over kidney samples were irreversibly deidentified, and no personal identifiers were
495 gathered, therefore they were exempt from IRB review (category 4). We engaged an external
496 honest broker who was responsible clinical data collection without disclosing personal
497 identifiable information. The University of Pennsylvania institutional review board (IRB) gave
498 its approval for the collection of human kidney tissue.

499 A portion of the tissue were formalin-fixed, paraffin-embedded, and stained with periodic acid-
500 Schiff. A local renal pathologist performed objective pathological scoring of the abnormal
501 parameters.

502 ***Immunostaining***

503 Paraffin blocks were sectioned. After deparaffinization, 1% bovine serum albumin was used for
504 blocking. Diluted primary antibodies on slides were incubated overnight (CD4 CST (Catalogue
505 #48374), IGKC: Biolegend (Catalogue #392702), and CD79A Abcam (Catalogue #ab79414). After
506 washing the sections with PBS, three times, secondary antibodies were used for 1h at room
507 temperature. The stains were imaged with OLYMPUS BX43 Microscope. Positive cells in ten
508 randomly selected fields were counted on each slide.

509 **Bioinformatic analysis**

510 ***Primary single nuclei and cell RNA-seq data processing***

511 Using Cell Ranger v6.0.1, FASTQ files from each 10X single nuclei run were processed (10X
512 Genomics). Gene expression matrices for each cell were produced using the human genome
513 reference GRCh38.

514 ***Data Processing and Computational Analyses***

515 After ambient RNA correction using “SoupX”(56) and doublet removal by “DoubletFinder”(57)
516 using default parameters, Seurat objects from the aligned outputs (from multiple samples) were
517 created where genes expressed in more than 3 cells and cells with at least 300 genes were retained.
518 Further, a merged Seurat object was obtained using “merge” function of Seurat v (4.0.3)(58). The
519 following QC filtering were used: (a) cells having n_{feature} counts of more than 3000 and less

520 than 200 as well as (b) more than 15% mitochondrial counts (for snRNA-seq data) and more than
521 50% mitochondrial counts (for scRNA-seq data) were filtered.

522

523 *Data Normalization and Cell Population Identification*

524 First, highly variable genes were identified using the method “vst”. The data was natural log
525 transformed and scaled. The scaled values were then subjected to principle component analysis
526 (PCA) for linear dimension reduction. We used the “harmony”(59) package by “RunHarmony”
527 function for batch effect correction. A shared nearest neighbor network was created based on
528 Euclidean distances between cells in a multidimensional PC space (the first 50 and 30 PCs were
529 used for snRNA-seq and scRNA-seq, respectively) and a fixed number of neighbors per cell, which
530 was used to generate a 2-dimensional Uniform Manifold Approximation and Projection (UMAP)
531 for visualization.

532 In order to identify cell-type markers, we used Seurat’s “FindAllMarkers” function of “Seurat”.
533 This method calculates log fold changes, percentages of expression within and outside a group,
534 and p-values of Wilcoxon-Rank Sum test comparing a group to all cells outside that specific group
535 including adjustment for multiple testing. A log-fold-change threshold of 0.25 and FDR<0.05 was
536 considered significant. These steps were performed on the snRNA-seq and scRNA-seq datasets,
537 separately. Clusters expressing multiple cell types specific marker genes were excluded as
538 potential doublets.

539

540

541

542 ***DEGs between diseased and healthy groups***

543 To identify DGEs between experimental groups, we utilized the "FindMarkers" tool for each cell
544 type and condition, a log-fold-change threshold of 0.25, and an FDR 0.05.

545 ***Single nuclei RNA-seq trajectory analysis***

546 PT, Injured PT cells and different types of fibroblasts were subclustered for the trajectory analysis.
547 The trajectory analysis was done in two steps. Different sub-types of iPT and stromal cells with
548 equal numbers were randomly subsampled and cell dataset object (CDS) was generated using
549 Monocle3(60, 61). After preprocessing, batch effects correction, the dataset was embedded for
550 dimension reduction and pseudotemporal ordering. We used the "order_cell" function and
551 indicated the PT as start point for "pseudotime" analysis. The "track genes" algorithm was used to
552 identify the DGEs along the trajectories, and genes with q values of 0.05 or higher were considered
553 significant.

554 ***Ligand–receptor interactions***

555 CellChat(35) repository was used to assess cellular interactions between different cell types and to
556 infer cell–cell communication networks from snRNA-seq data. Package CellChat v1.4.0 was used
557 to predict cell type-specific ligand–receptor interactions (1939 interactions). Only receptors and
558 ligands expressed in more than 10 cells in each cluster were considered. Probability and *P* values
559 were measured for each interaction.

560

561

562

563 ***Single nuclei ATAC-seq analysis***

564 Raw FASTQ files were aligned to the GRCh38 reference genome and quantified using Cell Ranger ATAC
565 (v. 1.1.0). The cell ranger outputs of four snATAC-seq datasets were embedded using Signac
566 (v.1.3.0)(62) to generate Signac object. Low-quality cells were removed from each snATAC object
567 using the following criteria: peak_region_fragments < 3000 & peak_region_fragments > 20000 &
568 pct_reads_in_peaks < 15 & nucleosome_signal > 4 & TSS.enrichment < 2). The filtered cells in
569 twenty objects were merged together using “merge” function in Seurat. Dimensional reduction
570 was done by singular value decomposition (SVD) of the TFIDF matrix and UMAP. Batch effect
571 was corrected using Harmony(59) via the “RunHarmony” function in Seurat. A KNN graph was
572 made to cluster cells using the Louvain algorithm.

573 ***Cluster annotation of snATAC-seq***

574 With the Signac "FindMarkers" function, peaks observed in at least 20% of cells were evaluated
575 for differentially accessible chromatin regions (DARs) between different cell types using a
576 likelihood ratio test, a log-fold-change threshold of 0.25, and an FDR of 0.05.

577 To annotate the genomic regions harboring snATAC-seq peaks, ChIPSeeker (v1.24.0)(63) was
578 used.

579 ***Motif Enrichment Analysis and Motif Activities***

580 The "AddMotifs" function of Signac was used to run a motif enrichment analysis after creating a
581 matrix of positional weights for motif candidates from JASPAR2020. The related function of
582 "RunChromVAR" and chromVAR (v.1.6.0)(64) were used to determine transcription factor
583 activity. The "FindMarkers" program was used to calculate the differences in motif activity

584 between clusters, and an FDR of 0.05 was deemed significant. The "FindMotif" tool was used to
585 carry out motif enrichment analysis on the differentially accessible regions.

586 *DARs between groups*

587 We used the "FindMarkers" function after selecting "DefaultAssay" as "peaks" to identify DARs
588 in each cell type and diseased and healthy conditions, with a log-fold-change threshold of 0.25 and
589 FDR<0.05. Peaks translated to related genes using ChIPSeeker (v1.21.1)(63).

590

591

592 *Annotation based on snRNA-seq and Integration snATAC-seq and snRNA-seq*

593 The "GeneActivity" tool in Signac was used to create a gene activity matrix following clustering
594 of the twenty integrated snATAC-seq datasets. Using protein-coding genes annotated in the
595 Ensembl database, this technique counts the ATAC peaks inside the gene body and 2 kb upstream
596 of the transcriptional start point. Next, log normalization was applied to the gene activity matrix.

597 The snRNA-seq dataset was utilized as a reference, and the "FindTransferAnchors" function was
598 used to discover matching genes between the snRNA-seq and snATAC-seq datasets by using
599 shared correlation patterns in the gene activity matrix and snRNA-seq dataset. Next, the predicted
600 labels within two datasets were identified using the "TransferData" method.

601

602 *Integration of snRNA-seq, scRNA-seq and snATAC-seq datasets*

603 In order to create a single snRNA-seq, scRNA-seq, and snATAC-seq dataset we used a step-by-
604 step integration method. First, we used our snRNA-seq dataset as a reference and the snATAC-
605 seq data (which gene activity was already calculated) to project to the snRNA-seq dataset using

606 “FindTransferAnchors”, and “TransferData” functions. Then the imputed snATAC-seq dataset
607 was merged with snRNA-seq dataset and after scaling, the data dimensions were reduced using
608 PCA and UMAP. After creating a single data matrix of snRNA-seq and snATAC-seq, the scRNA-
609 seq was projected to this dataset by finding the shared anchors. Then the imputed scRNA-seq
610 dataset was merged with integrated snRNA-seq, snATAC-seq datasets and after scaling, the data
611 dimensions were reduced using PCA and UMAP.

612

613

614

615 *SpRNA-seq data analysis*

616 The data was aligned using Space Ranger (v1.0.0) with reference genome GRCh38 and human
617 probe dataset (Visium_Human_Transcriptome_Probe_Set_v1.0_GRCh38). The data then was
618 loaded to make the Seurat object and normalized using SCT. This step was done for all seven
619 samples. The samples were merged together, using “merge” function of Seurat. Next, the data was
620 subjected to principle component analysis (PCA) for linear dimension reduction and Harmony was
621 used to integrate the datasets. A shared nearest neighbor network was created based on Euclidean
622 distances between cells in a multidimensional PC space (30 PCs were used) and a fixed number
623 of neighbors per cell, which was used to generate a 2-dimensional Uniform Manifold
624 Approximation and Projection (UMAP) for visualization.

625 In order to identify spot specific markers, Seurat’s “FindAllMarkers” function was used. In this
626 method log fold changes, percentages of expression within and outside a group, and p-values of
627 Wilcoxon-Rank Sum test comparing a group to all cells outside that specific group including

628 adjustment for multiple testing was calculated. A log-fold-change threshold of 0.25 and FDR<0.05
629 was considered as significant. Basic functions of Seurat were used for visualization.

630

631 *Deconvolution of SpRNA-seq Dataset*

632 Two different methods were used to deconvolute the spRNAseq data; the RCTD(65) method using
633 the default parameters and the CCA(66) method using Seurat. The “FindAnchors” function in
634 Seurat, the shared genes between two datasets was determined and cell type prediction was
635 performed using “TransferData” function and the prediction score of each cell type in each spot
636 was considered as the frequency of each cell type in the spot. The distribution score was calculated
637 as the number of spots with more than 10% probability of one cell type.

638 In order to determine the colocalization of the identified cells in each spot, Pearson correlation test
639 was performed which indicate the probability of co-existing of different cell types.

640

641 *Mapping sn/scRNA-seq to Spatial Location*

642 In order to map back the cell types identified in the dissociated data (sn/scRNA-seq datasets),
643 Celltrek(28) package was used. Firstly, the sn and scRNA-seq data were down sampled to 20,000
644 cells. Then, by using “traint” function, sn/scRNA-seq datasets were co-embedded with spRNAseq
645 datasets. Next, using the random forest model, single cells were mapped to their spatial locations.
646 This analysis was performed by merging snRNA-seq and immune cell types to enrich the dataset
647 for immune cells. Regarding colocalization, the “sColoc” function of the CellTrek was used.

648 In order to find the different cell type modules in the spRNAseq, spatial-weighted gene co-
649 expression analysis was performed.

650

651

652 **Finding microenvironments in spRNA-seq**

653 In order to identify microenvironments on the merged dataset the NMF reduction was performed
654 then, the clustering by default parameters using NMF reduction was done. In order to identify MEs
655 specific markers, Seurat's "FindAllMarkers" function was used.

656

657

658 ***ECM production score***

659 In order to calculate the extracellular matrix production (ECM), the proportion of the expressions
660 of the collagen, proteoglycan and glycoprotein(33) genes in each cells were calculated.

661 ***Bulk RNA-seq Analysis***

662 FASTQC was used to check the QC of the sequencing results. Next, the adapters and low-quality
663 bases were trimmed using TrimGalore (v0.4.5). The trimmed FASTQ files were aligned to the to
664 the human genome (hg19/GRCh37) using STAR (v2.7.3a)(67, 68) based on GENCODE v19
665 annotations(67, 68). The expression of different genes was measured using RSEM by calculating
666 uniquely mapped reads as transcripts per million (TPM).

667 ***Hierarchical clustering analysis***

668 ***Clustering of microdissected human kidney tubule samples based on FME-gene signature***

669 Hierarchical clustering was performed on the scaled TPM matrix of microdissected human tubules
670 datasets based on the FME-GS list. Ward's method with Euclidean distances was used to cluster the
671 datasets. The optimal number of clusters was determined by average silhouette method. After
672 clustering, the data was presented as a cluster dendrogram.

673 **Statistics**

674 The data were expressed as means \pm SEM. Independent sample t test was used to compare the
675 continuous variable in two groups and One-way ANOVA was used to compare the continuous
676 parameters between more than two groups followed by Bonferroni post hoc test for subgroup
677 comparisons. $P < 0.05$ was considered as a significance.

678

679 **Data Availability**

680 Raw data, processed data, and metadata from the snRNA-seq, scRNA-seq, snATAC-seq, and
681 spRNA-seq have been deposited in Gene Expression Omnibus (GEO) and the accession number
682 will be provided when it will be available. The human bulk kidney RNA-seq data are available
683 under following accession numbers: [GSE115098](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE115098) and [GSE173343](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE173343). The single cell and nuclear
684 expression and open chromatin and spatial data is also available at www.susztaklab.com.

685 **Code Availability**

686 All the codes used for the analysis were deposited on GitHub
687 (https://github.com/amin69upenn/Human_Kidney_Multiomics_and_Spatial_Atlas).

688

689 **Acknowledgement**

690 Work in the Susztak lab is supported by the NIH DK076077, DK087635 and DK105821. The
691 study is supported by GSK, Regeneron, Boehringer Ingelheim, and Novo Nordisk. The funders
692 have no influence on the reported results. The authors thank the Molecular Pathology and Imaging
693 Core (P30-DK050306) and Diabetes Research Center (P30-DK19525) at University of
694 Pennsylvania for their services.

695 **Competing interests**

696 KD and LM are employees of Regeneron Pharmaceuticals. GP, TB, EH, and LSB are an employee
697 of GSK. SP, CMB, and PG are employees of Boehringer Ingelheim. AK is the employee of Novo
698 Nordisk.

699

700 **Author Contributions**

701 AA, ZM, JF, RS, PD, GP, and TB performed experiments. AA, MSB, HL, SV, MSB, HY, and KC
702 performed computational analysis. KD, LM, EH, LSB, CAH, AK, PG, CMB, GP and ML offered
703 experimental and analytical suggestions. KS was responsible for overall design and oversight of
704 the experiments. MP performed pathological scorings. KS supervised the experiment. AA and KS
705 wrote the original draft. All authors contributed to and approved the final version of the
706 manuscript.

707

708

709

710

711 References

- 712 1. V. Gueutin, G. Deray, C. Isnard-Bagnis, Renal physiology. *Bull. Cancer* **99**, 237-249 (2012).
713 2. H. W. Smith, The fate of sodium and water in the renal tubules. *Bull. N. Y. Acad. Med.* **35**, 293
714 (1959).
715 3. P. Vart *et al.*, National trends in the prevalence of chronic kidney disease among racial/ethnic and
716 socioeconomic status groups, 1988-2016. *JAMA network open* **3**, e207932-e207932 (2020).
717 4. A. Yinusa, M. Faezipour, M. Faezipour, in *Healthcare*. (MDPI, 2022), vol. 10, pp. 1628.
718 5. Y. Kakitapalli, J. Ampolu, S. D. Madasu, M. S. Kumar, Detailed review of chronic kidney disease.
719 *Kidney Diseases* **6**, 85-91 (2020).
720 6. M. S. Balzer, T. Rohacs, K. Susztak, How Many Cell Types Are in the Kidney and What Do They Do?
721 *Annu. Rev. Physiol.* **84**, 507 (2022).
722 7. F. Schreiber, R. Kramann, Mapping the human kidney using single-cell genomics. *Nature Reviews*
723 *Nephrology* **18**, 347-360 (2022).
724 8. M. S. Balzer *et al.*, Single-cell analysis highlights differences in druggable pathways underlying
725 adaptive or fibrotic kidney regeneration. *Nature Communications* **13**, 1-18 (2022).
726 9. Z. Miao *et al.*, Single cell regulatory landscape of the mouse kidney highlights cellular
727 differentiation programs and disease targets. *Nature communications* **12**, 1-17 (2021).
728 10. Y. Muto *et al.*, Single cell transcriptional and chromatin accessibility profiling redefine cellular
729 heterogeneity in the adult human kidney. *Nature communications* **12**, 1-17 (2021).
730 11. P. C. Wilson *et al.*, The single-cell transcriptomic landscape of early human diabetic nephropathy.
731 *Proceedings of the National Academy of Sciences* **116**, 19619-19625 (2019).
732 12. M. D. Young *et al.*, Single-cell transcriptomes from human kidneys reveal the cellular identity of
733 renal tumors. *Science* **361**, 594-599 (2018).
734 13. E. E. Dixon, H. Wu, Y. Muto, P. C. Wilson, B. D. Humphreys, Spatially resolved transcriptomic
735 analysis of acute kidney injury in a female murine model. *J. Am. Soc. Nephrol.* **33**, 279-289 (2022).
736 14. E. E. Dixon, H. Wu, E. Sulvarán-Guel, J. Guo, B. D. Humphreys, Spatially resolved transcriptomics
737 and the kidney: many opportunities. *Kidney Int.*, (2022).
738 15. R. M. Ferreira *et al.*, Integration of spatial and single-cell transcriptomics localizes epithelial cell-
739 immune cross-talk in kidney injury. *JCI insight* **6**, (2021).
740 16. J. L. Marshall *et al.*, High-resolution Slide-seqV2 spatial transcriptomics enables discovery of
741 disease-specific cell neighborhoods and pathways. *IScience* **25**, 104097 (2022).
742 17. T. K. Chen, D. H. Knicely, M. E. Grams, Chronic kidney disease diagnosis and management: a
743 review. *JAMA* **322**, 1294-1304 (2019).
744 18. M. B. Palmer *et al.*, The role of glomerular epithelial injury in kidney function decline in patients
745 with diabetic kidney disease in the TRIDENT cohort. *Kidney international reports* **6**, 1066-1080
746 (2021).
747 19. F. Armutcu, Organ crosstalk: the potent roles of inflammation and fibrotic changes in the course
748 of organ interactions. *Inflamm. Res.* **68**, 825-839 (2019).
749 20. J. Majo, B. M. Klinkhammer, P. Boor, D. Tiniakos, Pathology and natural history of organ fibrosis.
750 *Curr. Opin. Pharmacol.* **49**, 82-89 (2019).
751 21. Z. Deng *et al.*, The extracellular matrix and mechanotransduction in pulmonary fibrosis. *The*
752 *International Journal of Biochemistry & Cell Biology* **126**, 105802 (2020).
753 22. B. D. Humphreys, Mechanisms of renal fibrosis. *Annu. Rev. Physiol.* **80**, 309-326 (2018).
754 23. T. Parimon, M. S. Hohmann, C. Yao, Cellular senescence: pathogenic mechanisms in lung fibrosis.
755 *Int. J. Mol. Sci.* **22**, 6214 (2021).

- 756 24. A. Makita *et al.*, The association between renal elasticity evaluated by real-time tissue
757 elastography and renal fibrosis. *Clin. Exp. Nephrol.* **25**, 981-987 (2021).
- 758 25. F. Lausecker, R. Lennon, M. J. Randles, The kidney matrisome in health, aging and disease. *Kidney*
759 *Int.*, (2022).
- 760 26. D. Zhou, Y. Liu, Understanding the mechanisms of kidney fibrosis. *Nature Reviews Nephrology* **12**,
761 68-70 (2016).
- 762 27. G. Z. Quinn *et al.*, Renal histologic analysis provides complementary information to kidney
763 function measurement for patients with early diabetic or hypertensive disease. *J. Am. Soc.*
764 *Nephrol.* **32**, 2863-2876 (2021).
- 765 28. R. Wei *et al.*, Spatial charting of single-cell transcriptomes in tissues. *Nat. Biotechnol.*, 1-10 (2022).
- 766 29. H. Wu, Y. Kirita, E. L. Donnelly, B. D. Humphreys, Advantages of single-nucleus over single-cell RNA
767 sequencing of adult kidney: rare cell types and novel cell states revealed in fibrosis. *J. Am. Soc.*
768 *Nephrol.* **30**, 23-32 (2019).
- 769 30. M. T. Grande *et al.*, Snail1-induced partial epithelial-to-mesenchymal transition drives renal
770 fibrosis in mice and can be targeted to reverse established disease. *Nat. Med.* **21**, 989-997 (2015).
- 771 31. J. Li *et al.*, Renal protective effects of empagliflozin via inhibition of EMT and aberrant glycolysis
772 in proximal tubules. *JCI insight* **5**, (2020).
- 773 32. C. Kuppe *et al.*, Decoding myofibroblast origins in human kidney fibrosis. *Nature* **589**, 281-286
774 (2021).
- 775 33. A. Naba *et al.*, The extracellular matrix: Tools and insights for the “omics” era. *Matrix Biol.* **49**, 10-
776 24 (2016).
- 777 34. Y. Sato, M. Tamura, M. Yanagita, Tertiary lymphoid tissues: A regional hub for kidney
778 inflammation. *Nephrology Dialysis Transplantation*, (2021).
- 779 35. S. Jin *et al.*, Inference and analysis of cell-cell communication using CellChat. *Nature*
780 *communications* **12**, 1-20 (2021).
- 781 36. A. Y. Kluger *et al.*, Class effects of SGLT2 inhibitors on cardiorenal outcomes. *Cardiovasc. Diabetol.*
782 **18**, 1-13 (2019).
- 783 37. J. Park *et al.*, Single-cell transcriptomics of the mouse kidney reveals potential cellular targets of
784 kidney disease. *Science* **360**, 758-763 (2018).
- 785 38. L. Zhang *et al.*, Genome-wide analysis of histone H3 lysine 4 trimethylation in peripheral blood
786 mononuclear cells of minimal change nephrotic syndrome patients. *Am. J. Nephrol.* **30**, 505-513
787 (2009).
- 788 39. T. A. Wynn, T. R. Ramalingam, Mechanisms of fibrosis: therapeutic translation for fibrotic disease.
789 *Nat. Med.* **18**, 1028-1040 (2012).
- 790 40. S. Djurdjaj, P. Boor, Cellular and molecular mechanisms of kidney fibrosis. *Mol. Aspects Med.* **65**,
791 16-36 (2019).
- 792 41. M. Liu, D. Gomez, Smooth muscle cell phenotypic diversity: At the crossroads of lineage tracing
793 and single-cell transcriptomics. *Arterioscler. Thromb. Vasc. Biol.* **39**, 1715-1723 (2019).
- 794 42. A. J. Pedroza *et al.*, Single-cell transcriptomic profiling of vascular smooth muscle cell phenotype
795 modulation in Marfan syndrome aortic aneurysm. *Arterioscler. Thromb. Vasc. Biol.* **40**, 2195-2211
796 (2020).
- 797 43. F. Zhang, X. Guo, Y. Xia, L. Mao, An update on the phenotypic switching of vascular smooth muscle
798 cells in the pathogenesis of atherosclerosis. *Cell. Mol. Life Sci.* **79**, 1-19 (2022).
- 799 44. H. Aghajanian *et al.*, Targeting cardiac fibrosis with engineered T cells. *Nature* **573**, 430-433
800 (2019).
- 801 45. H. Aghajanian, J. G. Rurik, J. A. Epstein, CAR-based therapies: opportunities for immuno-medicine
802 beyond cancer. *Nature Metabolism* **4**, 163-169 (2022).
- 803 46. J. G. Rurik *et al.*, CAR T cells produced in vivo to treat cardiac injury. *Science* **375**, 91-96 (2022).

- 804 47. P. Dhillon *et al.*, The nuclear receptor ESRR α protects from kidney disease by coupling metabolism
805 and differentiation. *Cell Metab.* **33**, 379-394. e378 (2021).
- 806 48. T. Doke *et al.*, Single-cell analysis identifies the interaction of altered renal tubules with basophils
807 orchestrating kidney fibrosis. *Nat. Immunol.*, 1-13 (2022).
- 808 49. E. Huang *et al.*, The roles of immune cells in the pathogenesis of fibrosis. *Int. J. Mol. Sci.* **21**, 5203
809 (2020).
- 810 50. F. Barone *et al.*, Stromal fibroblasts in tertiary lymphoid structures: a novel target in chronic
811 inflammation. *Front. Immunol.* **7**, 477 (2016).
- 812 51. Y. Huang *et al.*, Identification of novel genes associated with renal tertiary lymphoid organ
813 formation in aging mice. *PLoS One* **9**, e91850 (2014).
- 814 52. A. R. Kitching, Immunoaging within the kidney via injury-associated tertiary lymphoid tissue.
815 *Kidney Int.* **102**, 9-11 (2022).
- 816 53. R. Luo *et al.*, Tertiary lymphoid organs are associated with the progression of kidney damage and
817 regulated by interleukin-17A. *Theranostics* **11**, 117 (2021).
- 818 54. Y. Sato *et al.*, CD153/CD30 signaling promotes age-dependent tertiary lymphoid tissue expansion
819 and kidney injury. *The Journal of clinical investigation* **132**, (2022).
- 820 55. J. Zhao, S. Gu, A. McDermaid, Predicting outcomes of chronic kidney disease from EMR data based
821 on Random Forest Regression. *Math. Biosci.* **310**, 24-30 (2019).
- 822 56. M. D. Young, S. Behjati, SoupX removes ambient RNA contamination from droplet-based single-
823 cell RNA sequencing data. *Gigascience* **9**, (2020).
- 824 57. C. S. McGinnis, L. M. Murrow, Z. J. Gartner, DoubletFinder: Doublet Detection in Single-Cell RNA
825 Sequencing Data Using Artificial Nearest Neighbors. *Cell Syst* **8**, 329-337.e324 (2019).
- 826 58. Y. Hao *et al.*, Integrated analysis of multimodal single-cell data. *Cell*, (2021).
- 827 59. I. Korsunsky *et al.*, Fast, sensitive and accurate integration of single-cell data with Harmony.
828 *Nature methods* **16**, 1289-1296 (2019).
- 829 60. J. Cao *et al.*, The single-cell transcriptional landscape of mammalian organogenesis. *Nature* **566**,
830 496-502 (2019).
- 831 61. C. Trapnell *et al.*, Pseudo-temporal ordering of individual cells reveals dynamics and regulators of
832 cell fate decisions. *Nat. Biotechnol.* **32**, 381 (2014).
- 833 62. T. Stuart, A. Srivastava, C. Lareau, R. Satija, Multimodal single-cell chromatin analysis with Signac.
834 *BioRxiv*, (2020).
- 835 63. G. Yu, L.-G. Wang, Q.-Y. He, ChIPseeker: an R/Bioconductor package for ChIP peak annotation,
836 comparison and visualization. *Bioinformatics* **31**, 2382-2383 (2015).
- 837 64. A. N. Schep, B. Wu, J. D. Buenrostro, W. J. Greenleaf, chromVAR: inferring transcription-factor-
838 associated accessibility from single-cell epigenomic data. *Nature methods* **14**, 975-978 (2017).
- 839 65. D. M. Cable *et al.*, Robust decomposition of cell type mixtures in spatial transcriptomics. *Nat.*
840 *Biotechnol.* **40**, 517-526 (2022).
- 841 66. T. Stuart *et al.*, Comprehensive integration of single-cell data. *Cell* **177**, 1888-1902. e1821 (2019).
- 842 67. A. Dobin *et al.*, STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15-21 (2013).
- 843 68. J. Harrow *et al.*, GENCODE: the reference human genome annotation for The ENCODE Project.
844 *Genome Res.* **22**, 1760-1774 (2012).

845




Fig 1. Single cell resolution comprehensive human kidney multi-omics atlas. (A) Study overview. **(B)** Combined UMAP representation of 453,718 integrated human kidney sn/sc-RNA-seq and sn-ATAC-seq data. **(C)** UMAP of 223,438 human kidney snRNA-seq data and bubble dot plots of cluster specific marker genes. The size of the dot indicates the percent positive cells and the darkness of the color indicates average expression. **(D)** UMAP of 149,498 human kidney scRNA-seq data and bubble dot plots of cluster specific marker genes. The size of the dot indicates the percent positive cells and the darkness of the color indicates average expression. **(E)** UMAP of 80,845 human kidney snATAC-seq data and bubble dot plots of cluster specific marker genes using gene activity score. The size of the dot indicates the percent positive cells and the darkness of the color indicates average expression. Endo_GC; endothelial cells of glomerular capillary tuft, Endo_peritubular; endothelial cells of peritubular vessels, Endo_lymphatic; endothelial cells of lymphatic vessels, Mes; meseangial cells, GS_Stromal; glomerulosclerosis-specific stromal cells, VSMC/Myofib; vascular smooth muscle cells/myofibroblast, PEC; parietal epithelial cells, Podo; podocyte, PT_S1; proximal tubule segment 1, PT_S2; proximal tubule segment 2, PT_S3; proximal tubule segment 3, Injured_PT; injured proximal tubule cells, DLOH; thin descending loop of Henle, C_TAL; cortical thick ascending loop of Henle, M_TAL; medullary thick ascending loop of Henle, DCT; distal convoluted tubule, CNT; connecting tubule cells, PC; principal cells of collecting duct, IC_A; Type alpha intercalated cells, IC_B; Type beta intercalated cells, NK; natural killer cells, CD4T; T lymphocytes CD4+, CD8T; T lymphocytes CD8+, B_Naiive; Naive B lymphocyte, B_memory; memory B lymphocyte, RBC; red blood cells, Baso/Mast; basophil or mast cells, pDC; plasmacytoid dendritic cells, cDC; classical dendritic cells, Mac; macrophage, CD14_Mono; monocyte CD14+, CD16_Mono; monocyte CD16+.




Fig 2. Spatially resolved human kidney gene expression atlas. (A) Overview of the data generation and analysis of spRNA-seq. The spRNA-seq data was integrated with snRNA-seq information and spots were imputed to obtain near single cell level information using “CellTrek”. (B) Spatial location and specific marker genes expression of identified cell types in snRNA-seq. The dots show cells mapped back to their spatial location in the human kidney tissue. For each spatial location the original (H&E) image of the slide shown. The color indicates the gene expression level of specific marker genes, from blue to red indicates higher expression. Endo_GC; endothelial cells of glomerular capillary tuft, Endo_peritubular; endothelial cells of peritubular vessels, Endo_lymphatic; endothelial cells of lymphatic vessels, Mes; mesangial cells, GS_Stromal; glomerulosclerosis-specific stromal cells, VSMC/Myofib; vascular smooth muscle cells/myofibroblast, PEC; parietal epithelial cells, Podo; podocyte, PT_S1; proximal tubule segment 1, PT_S2; proximal tubule segment 2, PT_S3; proximal tubule segment 3, Injured_PT; injured proximal tubule cells, DLOH; thin descending loop of Henle, C_TAL; cortical thick ascending loop of Henle, M_TAL; medullary thick ascending loop of Henle, DCT; distal convoluted tubule, CNT; connecting tubule cells, PC; principal cells of collecting duct, IC_A; Type alpha intercalated cells, IC_B; Type beta intercalated cells, CD4T; T lymphocytes CD4+, B_Naive; Naive B lymphocyte, Mac; macrophage.




Fig 3. Spatial analysis highlights the proximity of the injured PT cells to the fibrotic niche. (A) The co-occurrence (Pearson correlation) of different kidney cells in the spatial transcriptome data after spot deconvolution using RCTD method using snRNA-seq as reference. The color indicates the degree of correlation. Higher correlation indicates the higher probability of co-occurrence of the cells. Different kidney compartments were encircled on the heatmap. **(B)** The spatial distance of kidney cells in the snRNA-seq data using sColoc of CellTrek. The circles indicate each cell type and the distance from the center indicates the lower frequency and distribution of cell types. The distance of the circles correlates with the distance of those cell types. **(C)** Bar graphs indicated the mean fractions of proximal tubule and injured proximal tubule cells in healthy control and diseased samples in snRNA-seq data. Bars indicate SEM. P values were calculated using independent *t* test. **(D)** The gene co-expression network indicates two types of injured PT in diseased human kidneys, left panel shows the heatmap of co-expressed genes. The right panels indicate the spatial location of the identified injured PT cells. The color scheme of the heatmap indicate the expressions of the genes in each iPT modules. **(E)** Two types of injured PT cells in snRNA-seq dataset. The bar graph shows the frequency of the different iPT types in healthy control and diseased samples. Violin plots show the different gene markers in PT and iPT cells. The heatmap indicates the enriched pathways for iPT-VCAM1+ and iPT-HAVCR1+ (lower panel). **(F)** UMAP representation of PT and iPT cell sub-clustering trajectory from PT to iPT-VCAM1+ and iPT-HAVCR1+ in snRNA-seq (Upper panels). Cells are colored by pseudotime and the arrow indicates the direction of the pseudotime. The heatmap shows the differentially expressed genes along the trajectory. The color scheme indicates the z scores of expression along the trajectory. **(G)** Representative feature plot of motif activity of specific transcription factors in iPT-VCAM1+ and iPT-HAVCR1+ using snATAC-seq data. Endo_GC; endothelial cells of glomerular capillary tuft, Endo_peritubular; endothelial cells of peritubular vessels, Endo_lymphatic; endothelial cells of lymphatic vessels, Mes; mesangial cells, GS_Stromal; glomerulosclerosis-specific stromal cells, VSMC/Myofib; vascular smooth muscle cells/myofibroblast, PEC; parietal epithelial cells, Podo; podocyte, PT_S1; proximal tubule segment 1, PT_S2; proximal tubule segment 2, PT_S3; proximal tubule segment 3, Injured_PT; injured proximal tubule cells, DLOH; thin descending loop of Henle, C_TAL; cortical thick ascending loop of Henle, M_TAL; medullary thick ascending loop of Henle, DCT; distal convoluted tubule, CNT; connecting tubule cells, PC; principal cells of collecting duct, IC_A; Type alpha intercalated cells, IC_B; Type beta intercalated cells, CD4T; T lymphocytes CD4+, B_Naive; Naive B lymphocyte, Mac; macrophage.




Fig 4. Spatially and transcriptionally resolved fibroblasts heterogeneity in human kidney fibrosis. (A) Extracellular matrix production score in different kidney cells in the sn/sc-RNA-seq. The color scheme indicates the ECM score in each cell type, calculated by the expression of the collagen, proteoglycan and glycoprotein genes. (B) The comparison between fractions of fibroblast_1 and VSMC/myofibroblast cells with the highest ECM score in healthy control and diseased samples. The bars indicate SEM. Independent t test was used to compare the fractions between two groups. (C) The ECM score in sprNA-seq data of healthy and diseased samples (upper panel). The color scheme indicates the z score. The spatial location of the cells in the regions with high ECM in sprNAseq data (lower panel). (D) UMAP representation of sub-clustering of stromal cell in snRNA-seq dataset (left panel). The bubble dot plots of cluster specific marker genes in the snRNA-seq. The size of the dot indicates the percent positive cells and the darkness of the color indicates average expression (right panel). (E) The spatial location and specific marker genes expression of identified stromal cell types in snRNA-seq. The dots show the cells mapped back to their spatial location in the human kidney. The original (H&E) image of the slide is shown side by side. The colors indicate the gene expression level of specific marker genes. (F) The heatmap of ECM score in the sub-clustered stromal cells (left panel). The heatmap of the fractions of different types of stromal cells in healthy control and diseased samples (right panel). (G) Transcription factor enrichment motifs in each stromal cell sub-cluster. The heatmap shows the z score of motif activity in each cell type using chromvar. Mes; mesangial cells, JGC; juxta glomerular cells, SERPINE1+; *SERPINE1* positive fibroblast, FAP+; *FAP* positive fibroblast, COL1A1+; collagen 1 producing fibroblasts, CR2+; *CR2* positive fibroblast, CXCL14+; *CXCL14* positive fibroblast, B2M+; *B2M* positive fibroblast, VSMC; vascular smooth muscle cells, MyoFib; myofibroblast.




Fig 5. The kidney fibrotic microenvironment relies on complex and organized epithelial, stromal, endothelial and immune cell interaction. (A) Different human kidney microenvironments in the (left panel) spRNA-seq dataset and the calculated ECM score (right panel). The color indicates ECM gene expression score in the kidney. (B) Key cell types located in the fibrotic microenvironment (upper panel). Fibrosis-associated immune cell aggregation in FMEs showing lymphocytes, plasma cells and macrophages (lower panel). The dots indicate cells mapped back to their spatial location using the merged spRNAseq, snRNA-seq and scRNA-seq datasets. (C) The bubble plot of expression of ligands and receptors in regions of FME in integrated sn/scRNA-seq data. The size of the dot indicates the percent positive cells and the darkness of the color indicates average expression (right panel). The gray indicates control and red indicates diseased group. (D) Ligands and receptor expression in specific cell types in FME regions (in spRNA-seq data). The color intensity indicates gene expression level and the dot indicates the location of the expressions. (E) Summary of the putative mechanism of the human kidney fibrosis. iPT; Injured_PT, MyoFib; Myofibroblast, CD4T; T lymphocytes CD4+, CD8T; T lymphocytes CD8+, B_Naive; Naive B lymphocyte, B_memory; memory B lymphocyte, Baso/Mast; basophil or mast cells, pDC; plasmacytoid dendritic cells, cDC; classical dendritic cells, Mac; macrophage, CD14_Mono; monocyte CD14+, CD16_Mono; monocyte CD16+.




Fig 6. Fibrotic microenvironment gene signature successfully predict disease prognosis in a large cohort of human kidney samples. (A) Clinical characteristics of 298 human kidney tubule RNA-seq samples. (B) Unbiased cluster dendrogram of 298 human kidney tubule bulk RNA-seq samples based on expression of FME genes. Clinical characteristics of each cluster. Chi-square test for categorical variables and one-way ANOVA for continuous variables were used to compare groups. (C) Unbiased cluster dendrograms of 218 human kidney tubule bulk RNA-seq samples with follow up eGFR based on expression of FME genes. The characteristics of each cluster were shown in the table. Chi-square test was used for categorical variables and one-way ANOVA for continuous variables was used to compare groups. The lower panel shows the Kaplan-Meier analysis of comparison of 3 the groups for renal survival. Renal survival was defined as cases reaching end stage renal disease or greater than 40% eGFR decline. (D) Heatmap of mean expression of top 30 genes cluster driving genes in 298 cross-sectional human kidney bulk RNA-seq (left panel) and 218 longitudinal human kidney bulk RNA (right panel). Top genes were defined based on the highest variation between groups using ANOVA. The heatmap shows the z score of mean gene expression in each cluster. (E) Enrichments of eGFR decline associated genes in sn/scRNA-seq and snATAC-seq clusters. The heatmap shows the percentage of the eGFR decline associated genes in each cluster with highest expression. HR; hazard ration, Endo; endothelial cells, Stroma; stromal cells, PEC; parietal epithelial cells, Podo; podocyte, PT; proximal tubule cells, DLOH; thin descending loop of Henle, LOH; loop of Henle, DCT; distal convoluted tubule, CNT; connecting tubule, PC; principal cells of collecting duct, IC_A; Type alpha intercalated cells,.